Timothy Voorhees
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Timothy Voorhees sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Timothy Voorhees: 3 sponsored US clinical trials, 2 recruiting.
Timothy Voorhees sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Polymorphic Post-Transplant Lymphoproliferative Disorder, with 1 trials.
Upper-quartile sponsor footprint
Timothy Voorhees sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
NCT06672705
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
NCT05786040
Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma
NCT05665725
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Timothy Voorhees pipeline
2 recruiting of 3 indexed (67% open); 1 completed (33%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Polymorphic Post-Transplant Lymphoproliferative Disorder (1 trial), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Timothy Voorhees: open-pipeline peers nationwide
Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Timothy Voorhees sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
Related
What to do with this Timothy Voorhees page
3 registered trials is a research-attention snapshot, not an endorsement of Timothy Voorhees or any single study.
- 2 of Timothy Voorhees's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Polymorphic Post-Transplant Lymphoproliferative Disorder is the condition Timothy Voorhees studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Polymorphic Post-Transplant Lymphoproliferative Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Timothy Voorhees pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.